entertainment -WSS

entertainment

author：explore 2025-10-01 21:35:17 - browse：61

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： FDA has safety concerns on CRISPR

WSS

Biden's order seeks to regulate AI risk without stifling innovation

How to use technology to prevent future drug shortages

Hospitals warn Medicare's drug payment fix is ‘unlawful’

How to use technology to prevent future drug shortages

First Opinion Podcast: How to protect health care in times of war

First Opinion Podcast: How to protect health care in times of war

explore

entertainment

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Biden's order seeks to regulate AI risk without stifling innovation

23andMe had bad news about my health. I wish a person had delivered it

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Malaria cases in Florida and Texas: Here’s what you need to know

Cassava reveals details — and problems — with Alzheimer's study

State Dept. review finds Biden bears some blame for Afghanistan failures

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

knowledge

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Senate panel to vote on hospitals, PBMs, prisoner care

Senate panel to vote on hospitals, PBMs, prisoner care

Maui's cultural, historic landmarks damaged in the devastating wildfires

Testing for cancer recurrence creates a new limbo for patients

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

focus

hotspot

knowledge

hotspot